8:40-9:00 |
Registration |
|
9:00-9:05 |
Opening Remark |
Shinji Harada
[Vice-president, Kumamoto University] |
9:05-9:10 |
History of Kumamoto AIDS Seminar |
Masafumi Takiguchi
[Director, Center for AIDS Research, Kumamoto University] |
Session
I |
9:10-10:25 k75l |
Chair:
Hiroaki Mitsuya |
|
O-01 |
Shinichi Oka
[NCGM / Kumamoto University, Japan]
|
HIV/AIDS in Asia; importance of cohort study |
|
O-02 |
Eddy Arnold
[CABM and Rutgers University, USA] |
HIV-1 reverse transcriptase structure, function,
inhibition, and resistance |
10:25-10:40
k15l @@Coffee Break |
Session
II |
10:40-11:40 k60l |
Chair:
Shuzo Matsushita |
|
O-03 |
Hiroaki Mitsuya
[Kumamoto University, Japan] |
Development of Central Nervous System-targeting Potent
Protease Inhibitors |
|
O-04 |
Hiroyuki Gatanaga
[NCGM / Kumamoto University, Japan] |
Naturally selected rilpivirine-resistant HIV-1 variants
by host
cellular immunity |
Session
III |
11:40-12:25
k45l |
Chair:
Masafumi Takiguchi |
|
O-05 |
Victor Appay
[INSERM, France] |
Exhaustion of primary immune resources in HIV infection |
12:25-14:00 k95l@@ Lunch |
Session
IV |
14:00-15:15 k75l |
Chair:
Takamasa Ueno |
|
O-06 |
Tetsuro Matano
[NIID / Kumamoto University, Japan] |
Vif can be a promising CD8 T cell target for HIV/SIV
control |
|
O-07 |
Thumbi Ndungfu
[University of KwaZulu-Natal., South-Africa] |
T cell immune responses and viral fitness as a pathway
to HIV vaccine design |
Session
V |
14:00-15:15 k75l |
Chair:
Tetsuro Matano |
|
O-08 |
Shinya Suzu
[Kumamoto University, Japan] |
Blood-borne fibrocytes as HIV-1 host cells |
|
O-09 |
Takeo Kuwata
[Kumamoto University, Japan] |
Identification of the Env region responsible for
the resistance to B404, a potent neutralizing antibody against SIV |
16:10-16:30
k20l @@Coffee Break |
Session
VI |
16:30-17:30 k60l |
Chair:
Yosuke Maeda |
|
O-10 |
Yoshio Koyanagi
[Kyoto University, Japan] |
Strategy of disrupting latent form of HIV-1 proviral
DNA |
|
O-11 |
Yasumasa Iwatani
[Nagoya Medical Center, Japan] |
Structural features of HIV-1 Vif-binding Interface
on antiviral APOBEC3 proteins |